Skip to content

Veeva Systems VEEV Deferred Foreign Income Tax Expense Benefit

Deferred Foreign Income Tax Expense Benefit at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
-$5.6M-224%

Other financials

Income statement

See full
Revenue$882.9M+16.3%
Gross profit$662.0M+13.1%
Operating income$273.1M+16.8%
Net income$260.9M+14.4%
EPS (diluted)$1.57+14.6%

Balance sheet

See full
Cash & equivalents$1.9B-3.5%
Total debt$103.1M+33.5%
Total equity$7.3B+17.6%
Total assets$9.1B+17.6%

Cash flow

See full
Operating cash flow$1.1B+28.5%
CapEx$2.3M
Free cash flow$110.6M

Valuation

See full
Market cap$24.9B-31.2%
Enterprise value$23.11B-32.6%
P/E26.5×-19.9×
P/S7.5×-5.2×

Profitability

See full
Gross margin75%-0.5pp
Operating margin28.8%+1.8pp
Net margin28.4%+1.0pp
FCF margin37.2%

Returns & leverage

See full
Return on equity13.9%-0.1pp
Debt / equity0.0×
Current ratio4.7×+0.1×

Where this comes from

Reported directly by Veeva Systems in its filing.

Tagged under the XBRL concept us-gaap:DeferredForeignIncomeTaxExpenseBenefit.

The official record: Veeva Systems’s 10-K, filed March 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veeva Systems's deferred foreign income tax expense benefit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veeva Systems's deferred foreign income tax expense benefit?
Veeva Systems (VEEV) reported deferred foreign income tax expense benefit of -$886.75K in Q4 2025.
How has Veeva Systems's deferred foreign income tax expense benefit changed year-over-year?
Veeva Systems's deferred foreign income tax expense benefit increased by 3.3% year-over-year, from -$917.25K to -$886.75K.
What is the long-term trend for Veeva Systems's deferred foreign income tax expense benefit?
Over 4 years (2022 to 2026), Veeva Systems's deferred foreign income tax expense benefit has grown at a -19.1% compound annual growth rate (CAGR), from $8.26M to -$3.55M.